SEARCH

SEARCH BY CITATION

References

  • Bacich D. J., Ramadan E., O’Keefe D. S. et al. (2002) Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J. Neurochem. 83, 2029.
  • Barinka C., Rinnova M., Sacha P., Rojas C., Majer P., Slusher B. S. and Konvalinka J. (2002) Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J. Neurochem. 80, 477487.
  • Barinka C., Mlcochova P., Sacha P., Hilgert I., Majer P., Slusher B. S., Horejsi V. and Konvalinka J. (2004a) Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur. J. Biochem. 271, 27822790.
  • Barinka C., Sacha P., Sklenar J., Man P., Bezouska K., Slusher B. S. and Konvalinka J. (2004b) Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci. 13, 16271635.
  • Bzdega T., Crowe S. L., Ramadan E. R., Sciarretta K. H., Olszewski R. T., Ojeifo O. A., Rafalski V. A., Wroblewska B. and Neale J. H. (2004) The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J. Neurochem. 89, 627635.
  • Case D. A., Darden T. A., Cheatham T. E. III et al. (2004) AMBER 8. University of California, San Francisco.
  • Chang S. S., Reuter V. E., Heston W. D., Bander N. H., Grauer L. S. and Gaudin P. B. (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 31923198.
  • Cornell W. D., Cieplak P., Bayly C. I. et al. (1995) A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J. Am. Chem. Soc. 117, 51795197.
  • Davis M. I., Bennett M. J., Thomas L. M. and Bjorkman P. J. (2005) Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl Acad. Sci. USA 102, 59815986.
  • DeLano W. L. (2002) The PyMOL User’s Manual. DeLano Scientific, San Carlos, CA, USA.
  • Ghadge G. D., Slusher B. S., Bodner A. et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl Acad. Sci. USA 100, 95549559.
  • Ghosh A. and Heston W. D. (2003) Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate 57, 140151.
  • Gregorakis A. K., Holmes E. H. and Murphy G. P. (1998) Prostate-specific membrane antigen: current and future utility. Semin. Urol. Oncol. 16, 212.
  • Harada C., Harada T., Slusher B. S., Yoshida K., Matsuda H. and Wada K. (2000) N-acetylated-alpha-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. Neurosci. Lett. 292, 134136.
  • Humphrey W., Dalke A. and Schulten K. (1996) VMD: visual molecular dynamics. J. Mol. Graph. 14, 3338.
  • Israeli R. S., Powell C. T., Corr J. G., Fair W. R. and Heston W. D. (1994) Expression of the prostate-specific membrane antigen. Cancer Res. 54, 18071811.
  • Jackson P. F., Cole D. C., Slusher B. S., Stetz S. L., Ross L. E., Donzanti B. A. and Trainor D. A. (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem. 39, 619622.
  • Kato T., Nagatsu T., Kimura T. and Sakakibara S. (1978) Fluorescence assay of x-prolyl dipeptidyl-aminopeptidase activity with a new fluorogenic substrate. Biochem. Med. 19, 351359.
  • Laskowski R. A. (1995) SURFNET: a program for visualizing molecular surfaces, cavities, and intermolecular interactions. J. Mol. Graph. 13, 323328.
  • Majer P., Jackson P. F., Delahanty G. et al. (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J. Med. Chem. 46, 19891996.
  • Majer P., Hin B., Stoermer D. et al. (2006) Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain. J. Med. Chem. 49, 28762885.
  • Mesters J. R., Barinka C., Li W., Tsukamoto T., Majer P., Slusher B. S., Konvalinka J. and Hilgenfeld R. (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 25, 13751384.
  • Morrison J. F. (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta. 185, 269286.
  • Murphy G., Ragde H., Kenny G. et al. (1995) Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15, 14731479.
  • Nan F., Bzdega T., Pshenichkin S., Wroblewski J. T., Wroblewska B., Neale J. H. and Kozikowski A. P. (2000) Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J. Med. Chem. 43, 772774.
  • Neale J. H., Olszewski R. T., Gehl L. M., Wroblewska B. and Bzdega T. (2005) The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 26, 477484.
  • Pangalos M. N., Neefs J. M., Somers M., Verhasselt P., Bekkers M., Van Der Helm L., Fraiponts E., Ashton D. and Gordon R. D. (1999) Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J. Biol. Chem. 274, 84708483.
  • Pinto J. T., Suffoletto B. P., Berzin T. M., Qiao C. H., Lin S., Tong W. P., May F., Mukherjee B. and Heston W. D. (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 2, 14451451.
  • Renneberg H., Friedetzky A., Konrad L., Kurek R., Weingartner K., Wennemuth G., Tunn U. W. and Aumuller G. (1999) Prostate specific membrane antigen (PSM) is expressed in various human tissues: implication for the use of PSM reverse transcription polymerase chain reaction to detect hematogenous prostate cancer spread. Urol. Res. 27, 2327.
  • Robinson M. B., Blakely R. D., Couto R. and Coyle J. T. (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha- linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 262, 14 49814 506.
  • Schmidt B., Anastasiadis A. G., Seifert H. H., Franke K. H., Oya M. and Ackermann R. (2003) Detection of circulating prostate cells during radical prostatectomy by standardized PSMA RT-PCR: association with positive lymph nodes and high malignant grade. Anticancer Res. 23, 39913999.
  • Sedo A., Malik R. and Krepela E. (1998) Dipeptidyl peptidase IV in C6 rat glioma cell line differentiation. Biol. Chem. 379, 3944.
  • Serval V., Barbeito L., Pittaluga A., Cheramy A., Lavielle S. and Glowinski J. (1990) Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L- glutamate. J. Neurochem. 55, 3946.
  • Silver D. A., Pellicer I., Fair W. R., Heston W. D. and Cordon-Cardo C. (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 8185.
  • Slusher B. S., Vornov J. J., Thomas A. G. et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5, 13961402.
  • Sokoloff R. L., Norton K. C., Gasior C. L., Marker K. M. and Grauer L. S. (2000) A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 43, 150157.
  • Subasinghe N., Schulte M., Chan M. Y., Roon R. J., Koerner J. F. and Johnson R. L. (1990) Synthesis of acyclic and dehydroaspartic acid analogues of Ac- Asp-Glu-OH and their inhibition of rat brain N-acetylated alpha- linked acidic dipeptidase (NAALA dipeptidase). J. Med. Chem. 33, 27342744.
  • Troyer J. K., Beckett M. L. and Wright G. L. Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 62, 552558.
  • Tsai G., Dunham K. S., Drager U., Grier A., Anderson C., Collura J. and Coyle J. T. (2003) Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse 50, 285292.
  • Tsukamoto T., Flanary J. M., Rojas C., Slusher B. S., Valiaeva N. and Coward J. K. (2002) Phosphonate and phosphinate analogues of N-acylated gamma-glutamylglutamate. Potent inhibitors of glutamate carboxypeptidase II. Bioorg. Med. Chem. Lett. 12, 21892192.
  • Tsukamoto T., Majer P., Vitharana D. et al. (2005) Enantiospecificity of glutamate carboxypeptidase II inhibition. J. Med. Chem. 48, 23192324.
  • Vitharana D., France J. E., Scarpetti D., Bonneville G. W., Majer P. and Tsukamoto T. (2002) Synthesis and biological evaluation of (R)- and (S)-2-(phosphonomethyl)pentanedioic acids as inhibitors of glutamate carboxypeptidase II. Tetrahedron Asymmetry 13, 16091614.
  • Whelan J. (2000) NAALADase inhibitors: a novel approach to glutamate regulation. Drug Discov. Today 5, 171172.
  • Xiao Z., Adam B. L., Cazares L. H., Clements M. A., Davis J. W., Schellhammer P. F., Dalmasso E. A. and Wright G. L. Jr (2001) Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61, 60296033.
  • Zhang W., Slusher B., Murakawa Y., Wozniak K. M., Tsukamoto T., Jackson P. F. and Sima A. A. (2002) GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J. Neurol. Sci. 194, 2128.
  • Zhou J., Neale J. H., Pomper M. G. and Kozikowski A. P. (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov. 4, 10151026.